Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Patrick Aebischer | M | 70 |
Vandria SA
 Vandria SA Pharmaceuticals: MajorHealth Technology Vandria SA is a Swiss-based company that specializes in mitochondrial therapeutics. The company is based in Lausanne, Switzerland. The company is developing mitophagy inducers that rejuvenate cells to treat age-related and chronic diseases. Its lead program, VNA-318, is a brain-penetrant, patent-protected, mitophagy inducer that has shown to improve memory and learning and to have strong disease-modifying effects in models of neurodegenerative diseases such as Alzheimer's and Parkinson's disease. Vandria is also developing mitophagy-inducing small molecules to address muscle, lung, and liver diseases, as well as a separate program that targets ferroptosis. The company was founded by Patrick Aebischer, Chris Rinsch, and Johan Auwerx in 2021 and has raised $20.60m in venture finance. Klaus Dugi has been the CEO of the company since 2021.
NanoDimension Management Ltd.
 NanoDimension Management Ltd. Investment ManagersFinance NanoDimension Management (NanoDimension) Ltd is a venture capital firm founded in 2002 by Aymeric Sallin. The firm is headquartered in George Town. | 7 years |
| Todd Krueger | M | - |
AOBiome Therapeutics, Inc.
 AOBiome Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology AOBiome Therapeutics, Inc. develops microbiome-targeted therapies for local, nasal and systemic inflammatory conditions. Its portfolio includes three clinical-stage programs, a Phase 2b study to treat patients with acne vulgaris, a Phase 2 trial to reduce elevated blood pressure, and a Phase 1b/2a clinical trial in allergic rhinitis, as well as earlier-stage preclinical programs targeting diverse inflammatory indications. The company was founded by Jamie Heywood, David Whitlock and Lenny Barshack in 2013 and is headquartered in Cambridge, MA. | - |
| Peter Liddiard | M | - |
NanoDimension Management Ltd.
NanoDimension Management Ltd. Investment ManagersFinance NanoDimension Management (NanoDimension) Ltd is a venture capital firm founded in 2002 by Aymeric Sallin. The firm is headquartered in George Town. | 5 years |
| Jamie Heywood | M | - |
AOBiome Therapeutics, Inc.
AOBiome Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology AOBiome Therapeutics, Inc. develops microbiome-targeted therapies for local, nasal and systemic inflammatory conditions. Its portfolio includes three clinical-stage programs, a Phase 2b study to treat patients with acne vulgaris, a Phase 2 trial to reduce elevated blood pressure, and a Phase 1b/2a clinical trial in allergic rhinitis, as well as earlier-stage preclinical programs targeting diverse inflammatory indications. The company was founded by Jamie Heywood, David Whitlock and Lenny Barshack in 2013 and is headquartered in Cambridge, MA. | - |
| Annalisa Jenkins | M | 58 |
AOBiome Therapeutics, Inc.
AOBiome Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology AOBiome Therapeutics, Inc. develops microbiome-targeted therapies for local, nasal and systemic inflammatory conditions. Its portfolio includes three clinical-stage programs, a Phase 2b study to treat patients with acne vulgaris, a Phase 2 trial to reduce elevated blood pressure, and a Phase 1b/2a clinical trial in allergic rhinitis, as well as earlier-stage preclinical programs targeting diverse inflammatory indications. The company was founded by Jamie Heywood, David Whitlock and Lenny Barshack in 2013 and is headquartered in Cambridge, MA. | 6 years |
| Aymeric Sallin | M | 50 |
NanoDimension Management Ltd.
NanoDimension Management Ltd. Investment ManagersFinance NanoDimension Management (NanoDimension) Ltd is a venture capital firm founded in 2002 by Aymeric Sallin. The firm is headquartered in George Town. | 22 years |
| Daniel Bach | M | - |
Vandria SA
Vandria SA Pharmaceuticals: MajorHealth Technology Vandria SA is a Swiss-based company that specializes in mitochondrial therapeutics. The company is based in Lausanne, Switzerland. The company is developing mitophagy inducers that rejuvenate cells to treat age-related and chronic diseases. Its lead program, VNA-318, is a brain-penetrant, patent-protected, mitophagy inducer that has shown to improve memory and learning and to have strong disease-modifying effects in models of neurodegenerative diseases such as Alzheimer's and Parkinson's disease. Vandria is also developing mitophagy-inducing small molecules to address muscle, lung, and liver diseases, as well as a separate program that targets ferroptosis. The company was founded by Patrick Aebischer, Chris Rinsch, and Johan Auwerx in 2021 and has raised $20.60m in venture finance. Klaus Dugi has been the CEO of the company since 2021.
NanoDimension Management Ltd.
NanoDimension Management Ltd. Investment ManagersFinance NanoDimension Management (NanoDimension) Ltd is a venture capital firm founded in 2002 by Aymeric Sallin. The firm is headquartered in George Town. | 5 years |
| Chris Rinsch | M | - |
Vandria SA
Vandria SA Pharmaceuticals: MajorHealth Technology Vandria SA is a Swiss-based company that specializes in mitochondrial therapeutics. The company is based in Lausanne, Switzerland. The company is developing mitophagy inducers that rejuvenate cells to treat age-related and chronic diseases. Its lead program, VNA-318, is a brain-penetrant, patent-protected, mitophagy inducer that has shown to improve memory and learning and to have strong disease-modifying effects in models of neurodegenerative diseases such as Alzheimer's and Parkinson's disease. Vandria is also developing mitophagy-inducing small molecules to address muscle, lung, and liver diseases, as well as a separate program that targets ferroptosis. The company was founded by Patrick Aebischer, Chris Rinsch, and Johan Auwerx in 2021 and has raised $20.60m in venture finance. Klaus Dugi has been the CEO of the company since 2021. | - |
| Douglas P. Rosefsky | M | - |
AOBiome Therapeutics, Inc.
AOBiome Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology AOBiome Therapeutics, Inc. develops microbiome-targeted therapies for local, nasal and systemic inflammatory conditions. Its portfolio includes three clinical-stage programs, a Phase 2b study to treat patients with acne vulgaris, a Phase 2 trial to reduce elevated blood pressure, and a Phase 1b/2a clinical trial in allergic rhinitis, as well as earlier-stage preclinical programs targeting diverse inflammatory indications. The company was founded by Jamie Heywood, David Whitlock and Lenny Barshack in 2013 and is headquartered in Cambridge, MA. | 6 years |
| peter vlasselaer | M | - |
NanoDimension Management Ltd.
NanoDimension Management Ltd. Investment ManagersFinance NanoDimension Management (NanoDimension) Ltd is a venture capital firm founded in 2002 by Aymeric Sallin. The firm is headquartered in George Town. | 5 years |
| Karin Lykke-Hartmann | M | - | - | |
| Alison Palmer | F | - |
NanoDimension Management Ltd.
NanoDimension Management Ltd. Investment ManagersFinance NanoDimension Management (NanoDimension) Ltd is a venture capital firm founded in 2002 by Aymeric Sallin. The firm is headquartered in George Town. | 3 years |
| Ryan Schubert | M | - |
NanoDimension Management Ltd.
NanoDimension Management Ltd. Investment ManagersFinance NanoDimension Management (NanoDimension) Ltd is a venture capital firm founded in 2002 by Aymeric Sallin. The firm is headquartered in George Town. | 3 years |
| Jim Hoffman | M | - |
AOBiome Therapeutics, Inc.
AOBiome Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology AOBiome Therapeutics, Inc. develops microbiome-targeted therapies for local, nasal and systemic inflammatory conditions. Its portfolio includes three clinical-stage programs, a Phase 2b study to treat patients with acne vulgaris, a Phase 2 trial to reduce elevated blood pressure, and a Phase 1b/2a clinical trial in allergic rhinitis, as well as earlier-stage preclinical programs targeting diverse inflammatory indications. The company was founded by Jamie Heywood, David Whitlock and Lenny Barshack in 2013 and is headquartered in Cambridge, MA. | 9 years |
| Kostas Kaloulis | M | - |
NanoDimension Management Ltd.
NanoDimension Management Ltd. Investment ManagersFinance NanoDimension Management (NanoDimension) Ltd is a venture capital firm founded in 2002 by Aymeric Sallin. The firm is headquartered in George Town. | 6 years |
| Jean-François Ricci | M | - |
NanoDimension Management Ltd.
NanoDimension Management Ltd. Investment ManagersFinance NanoDimension Management (NanoDimension) Ltd is a venture capital firm founded in 2002 by Aymeric Sallin. The firm is headquartered in George Town. | 6 years |
| Carl Pabo | M | - |
NanoDimension Management Ltd.
NanoDimension Management Ltd. Investment ManagersFinance NanoDimension Management (NanoDimension) Ltd is a venture capital firm founded in 2002 by Aymeric Sallin. The firm is headquartered in George Town. | 16 years |
| Jun Wang | M | 48 |
AOBiome Therapeutics, Inc.
AOBiome Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology AOBiome Therapeutics, Inc. develops microbiome-targeted therapies for local, nasal and systemic inflammatory conditions. Its portfolio includes three clinical-stage programs, a Phase 2b study to treat patients with acne vulgaris, a Phase 2 trial to reduce elevated blood pressure, and a Phase 1b/2a clinical trial in allergic rhinitis, as well as earlier-stage preclinical programs targeting diverse inflammatory indications. The company was founded by Jamie Heywood, David Whitlock and Lenny Barshack in 2013 and is headquartered in Cambridge, MA. | - |
| Phil DiGiacomo | M | - |
NanoDimension Management Ltd.
NanoDimension Management Ltd. Investment ManagersFinance NanoDimension Management (NanoDimension) Ltd is a venture capital firm founded in 2002 by Aymeric Sallin. The firm is headquartered in George Town. | 8 years |
| Andre Chatelain | M | - |
NanoDimension Management Ltd.
NanoDimension Management Ltd. Investment ManagersFinance NanoDimension Management (NanoDimension) Ltd is a venture capital firm founded in 2002 by Aymeric Sallin. The firm is headquartered in George Town. | 22 years |
| Eric Moessinger | M | 43 |
NanoDimension Management Ltd.
NanoDimension Management Ltd. Investment ManagersFinance NanoDimension Management (NanoDimension) Ltd is a venture capital firm founded in 2002 by Aymeric Sallin. The firm is headquartered in George Town. | 16 years |
| Kirill Kuzmichev | M | - |
NanoDimension Management Ltd.
NanoDimension Management Ltd. Investment ManagersFinance NanoDimension Management (NanoDimension) Ltd is a venture capital firm founded in 2002 by Aymeric Sallin. The firm is headquartered in George Town. | 11 years |
| Richard Coles | M | - |
NanoDimension Management Ltd.
NanoDimension Management Ltd. Investment ManagersFinance NanoDimension Management (NanoDimension) Ltd is a venture capital firm founded in 2002 by Aymeric Sallin. The firm is headquartered in George Town. | 18 years |
| Jonathan Nicholson | M | - |
NanoDimension Management Ltd.
NanoDimension Management Ltd. Investment ManagersFinance NanoDimension Management (NanoDimension) Ltd is a venture capital firm founded in 2002 by Aymeric Sallin. The firm is headquartered in George Town. | 19 years |
| Odile Rundquist | M | - |
Vandria SA
Vandria SA Pharmaceuticals: MajorHealth Technology Vandria SA is a Swiss-based company that specializes in mitochondrial therapeutics. The company is based in Lausanne, Switzerland. The company is developing mitophagy inducers that rejuvenate cells to treat age-related and chronic diseases. Its lead program, VNA-318, is a brain-penetrant, patent-protected, mitophagy inducer that has shown to improve memory and learning and to have strong disease-modifying effects in models of neurodegenerative diseases such as Alzheimer's and Parkinson's disease. Vandria is also developing mitophagy-inducing small molecules to address muscle, lung, and liver diseases, as well as a separate program that targets ferroptosis. The company was founded by Patrick Aebischer, Chris Rinsch, and Johan Auwerx in 2021 and has raised $20.60m in venture finance. Klaus Dugi has been the CEO of the company since 2021. | - |
| Luc Bauer | M | - |
NanoDimension Management Ltd.
NanoDimension Management Ltd. Investment ManagersFinance NanoDimension Management (NanoDimension) Ltd is a venture capital firm founded in 2002 by Aymeric Sallin. The firm is headquartered in George Town. | 22 years |
| Henrik Stage | M | - | - | |
| Jacob Falck Hansen | M | - | - |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Spiros Jamas | M | 63 |
AOBiome Therapeutics, Inc.
AOBiome Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology AOBiome Therapeutics, Inc. develops microbiome-targeted therapies for local, nasal and systemic inflammatory conditions. Its portfolio includes three clinical-stage programs, a Phase 2b study to treat patients with acne vulgaris, a Phase 2 trial to reduce elevated blood pressure, and a Phase 1b/2a clinical trial in allergic rhinitis, as well as earlier-stage preclinical programs targeting diverse inflammatory indications. The company was founded by Jamie Heywood, David Whitlock and Lenny Barshack in 2013 and is headquartered in Cambridge, MA. | 6 years |
| Andrew Gengos | M | 59 |
AOBiome Therapeutics, Inc.
AOBiome Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology AOBiome Therapeutics, Inc. develops microbiome-targeted therapies for local, nasal and systemic inflammatory conditions. Its portfolio includes three clinical-stage programs, a Phase 2b study to treat patients with acne vulgaris, a Phase 2 trial to reduce elevated blood pressure, and a Phase 1b/2a clinical trial in allergic rhinitis, as well as earlier-stage preclinical programs targeting diverse inflammatory indications. The company was founded by Jamie Heywood, David Whitlock and Lenny Barshack in 2013 and is headquartered in Cambridge, MA. | - |
| Charles Michaud | M | 57 |
AOBiome Therapeutics, Inc.
AOBiome Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology AOBiome Therapeutics, Inc. develops microbiome-targeted therapies for local, nasal and systemic inflammatory conditions. Its portfolio includes three clinical-stage programs, a Phase 2b study to treat patients with acne vulgaris, a Phase 2 trial to reduce elevated blood pressure, and a Phase 1b/2a clinical trial in allergic rhinitis, as well as earlier-stage preclinical programs targeting diverse inflammatory indications. The company was founded by Jamie Heywood, David Whitlock and Lenny Barshack in 2013 and is headquartered in Cambridge, MA. | 1 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 26 | 83.87% |
| Switzerland | 4 | 12.90% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Klaus Dugi
- Personal Network
